Alere Inc (Waltham, MA) announced two recent transactions. Alere signed an agreement to sell its BBI business to Exponent Private Equity LLP (London, England) for a total purchase price of approximately $164 million including up to $47 million in contingent consideration. The final purchase price is subject to a working capital adjustment. The close of the BBI sale is subject to regulatory approvals. Additionally, Alere has acquired substantially all of the assets of US Diagnostics (USD) (Huntsville, AL) for $60 million in cash. USD is a provider of drug testing devices and is currently a distributor of Alere Toxicology products. The company expects the acquisition of USD to be immediately accretive, deliver strong returns, and provide access to an expanded customer base with additional opportunities for selling other Alere Toxicology solutions and other business synergies.
Market Pulse transactions shown herein are provided as a matter of public record. These transactions have been compiled from press releases, corporate announcements and other public sources to provide an overview of acquisition and merger activities within the healthcare and life sciences sectors.